Zacks Research Has Pessimistic Outlook of IRWD Q3 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Zacks Research cut their Q3 2026 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a research note issued to investors on Wednesday, March 26th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings of $0.07 per share for the quarter, down from their previous estimate of $0.08. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2026 earnings at $0.06 EPS and FY2026 earnings at $0.23 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm had revenue of $90.55 million for the quarter, compared to analyst estimates of $93.85 million.

A number of other research analysts have also weighed in on the stock. Craig Hallum dropped their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. JMP Securities cut their price target on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a report on Thursday, January 30th. Finally, StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.60.

Ironwood Pharmaceuticals Trading Down 3.4 %

NASDAQ IRWD opened at $1.41 on Friday. The company has a market cap of $225.64 million, a P/E ratio of -47.00 and a beta of 0.37. The company has a fifty day simple moving average of $2.04 and a 200 day simple moving average of $3.39. Ironwood Pharmaceuticals has a 12-month low of $1.34 and a 12-month high of $8.64.

Insiders Place Their Bets

In other news, CMO Michael Shetzline sold 41,269 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the transaction, the chief marketing officer now owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. This represents a 6.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Thomas A. Mccourt sold 139,064 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the sale, the chief executive officer now directly owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. The trade was a 10.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 192,381 shares of company stock worth $338,591 over the last quarter. 12.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in IRWD. State Street Corp lifted its stake in Ironwood Pharmaceuticals by 7.3% in the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after purchasing an additional 677,024 shares during the last quarter. Deutsche Bank AG raised its stake in Ironwood Pharmaceuticals by 47.4% in the fourth quarter. Deutsche Bank AG now owns 1,567,535 shares of the biotechnology company’s stock worth $6,944,000 after buying an additional 504,336 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Ironwood Pharmaceuticals by 5.5% in the 4th quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company’s stock valued at $40,163,000 after purchasing an additional 469,043 shares during the period. Pacer Advisors Inc. lifted its position in Ironwood Pharmaceuticals by 4.0% during the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock valued at $51,967,000 after buying an additional 450,949 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter valued at $1,888,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.